統合失調症薬の市場規模、シェア、成長分析、薬剤クラス別、治療別、流通チャネル別、地域別 - 産業予測、2024年～2031年

統合失調症薬の世界市場規模は2022年に75億米ドルと評価され、2023年の79億米ドルから2031年には119億4,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは5.3%で推移する見通しです。

統合失調症は、人間関係、家族関係、教育、雇用など、人生の様々な重要な分野に大きな影響を及ぼし、一般人口の2～3倍の早死にリスクの高まりにつながります。この疾患は全世界で約2,400万人、人口の0.32％が罹患しており、成人の有病率は0.45％と高いです。特に、この疾患は女性よりも男性に1.4倍多く発症し、発症年齢のピークは男性で20～28歳、女性で25～32歳です。インドと中国の新興市場は、良好なヘルスケア改革、高齢化、健康意識の高まり、費用対効果の高い解決策などにより、統合失調症薬市場に大きな成長機会をもたらしています。未発達地域における認知度の不足が市場拡大を阻害しているなどの課題はあるもの、この成長軌道はアジア太平洋地域で特に顕著です。一方、米国の統合失調症薬市場は、今後の予測期間においても持続的なCAGRを維持すると予測されています。これらの洞察は、統合失調症治療分野の利害関係者にとって有望な展望を示しており、世界的に認知度や準備レベルが異なる中、技術革新やリーチ拡大の道を提供するものです。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場のエコシステム
• PESTEL分析
• 価格分析

統合失調症薬市場：薬剤クラス別

• 市場概要
• 第二世代抗精神病薬
  • リスパダール（リスペリドン）
  • インヴェガ（パリペリドン）
  • ジプレキサ（オランザピン）
  • ジオドン（ジプラシドン）
  • セロクエル（クエチアピン）
  • ラツーダ（ルラシドン）
  • アリスタダ（アリピプラゾールラウロキシル）
  • ファナプト（イロペリドン）
  • サフリス（アセナピン）
  • ヴレイラー（カリプラジン）
• 第三世代抗精神病薬
  • エビリファイ（アリピプラゾール）
• その他
  • 第一世代抗精神病薬
  • ジェネリック

統合失調症薬市場：治療別

• 市場概要
• 経口抗精神病薬
• 注射用抗精神病薬

統合失調症薬市場：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

統合失調症薬市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Johnson & Johnson（US）
• Bristol-Myers Squibb（US）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• AstraZeneca（UK）
• Sumitomo Dainippon Pharma（Japan）
• Eli Lilly and Company（US）
• Alkermes Plc（Ireland）
• Vanda Pharmaceuticals Inc.（US）
• Allergan（Ireland）
• Pfizer Inc.（US）
• H. Lundbeck A/S（Denmark）
• Janssen Pharmaceuticals, Inc.（US）
• Minerva Neurosciences（US）
• Reliance Life Sciences（India）
• Novartis AG（Switzerland）
• GlaxoSmithKline（UK）
• Merck KGaA（Germany）
• Takeda Pharmaceuticals（Japan）
• AbbVie（US）
• Acadia Pharmaceuticals（US）
• Karuna Therapeutics（US）

Global Schizophrenia Drugs Market size was valued at USD 7.50 billion in 2022 and is poised to grow from USD 7.90 billion in 2023 to USD 11.94 billion by 2031, growing at a CAGR of 5.3% in the forecast period (2024-2031).

Schizophrenia significantly impacts various critical areas of life, including personal relationships, family dynamics, education, and employment, leading to a heightened risk of premature death-two to three times higher than the general population. The condition affects approximately 24 million people globally, translating to 0.32% of the population, with a higher prevalence of 0.45% among adults. Notably, the disorder occurs 1.4 times more frequently in men than women, with peak onset ages ranging from 20 to 28 years for males and 25 to 32 years for females. Emerging markets in India and China present substantial growth opportunities for the schizophrenia drug market, driven by favorable healthcare reforms, an aging population, increasing health awareness, and cost-effective solutions. This growth trajectory is particularly strong in the Asia Pacific region, despite challenges such as a lack of awareness in underdeveloped areas hindering market expansion. Meanwhile, the US schizophrenia drug market is projected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast period. These insights indicate a promising landscape for stakeholders in the schizophrenia treatment sector, offering avenues for innovation and expanded reach amidst varying global awareness and preparedness levels.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Schizophrenia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Schizophrenia Drugs Market Segmental Analysis

Global Schizophrenia Drugs Market is segmented on the drug class, treatment, distribution channel and region. By drug class, market is segmented into second-generation antipsychotics, third-generation antipsychotics, and others. By treatment, market is segmented into oral antipsychotics, and injectable antipsychotics. By distribution channel, market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market is poised for significant growth, driven by an increasing prevalence of schizophrenia and an escalating demand for improved healthcare infrastructure. As governments partner with healthcare facilities to enhance treatment safety and availability, more patients are receiving adequate therapeutic interventions. Ongoing clinical studies aimed at developing innovative drugs targeting novel molecular pathways are set to address pressing unmet needs in schizophrenia management. This proactive approach by pharmaceutical companies to explore new therapeutic avenues and strengthen their drug pipelines is expected to captivate both healthcare providers and patients, thus propelling the market forward.

Restraints in the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market faces significant restraints that hinder its growth potential. A critical barrier is the insufficient awareness and understanding of mental health issues, particularly in developing countries, where stigma and lack of resources further complicate treatment accessibility. Furthermore, the high costs associated with schizophrenia medications and treatments limit patient access and reduce overall market demand. Additionally, adverse effects associated with many antipsychotic medications contribute to patients' reluctance to initiate or adhere to treatment regimens, undermining confidence in available therapies. Together, these factors create a challenging landscape that slows the overall expansion of the market.

Market Trends of the Global Schizophrenia Drugs Market

The Global Schizophrenia Drugs market is experiencing a transformative shift driven by an evolving understanding of the complex mechanisms underlying schizophrenia. With traditional views focusing on dopamine dysregulation now expanded to include multifaceted structural and chemical abnormalities, drug development is increasingly targeting novel pathways. Research is gaining momentum in exploring trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors, which promise to offer safer and more effective therapeutic options. This diversification in targets is paving the way for innovative treatments, thus propelling market growth as pharmaceutical companies adapt to these advancements and strive to meet the evolving needs of patients globally.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• PESTEL Analysis
• Pricing Analysis

Schizophrenia Drugs Market, By Drug Class

• Market Overview
• Second-Generation Antipsychotics
  • Risperdal (Risperidone)
  • Invega (Paliperidone)
  • Zyprexa (Olanzapine)
  • Geodon (Ziprasidone)
  • Seroquel (Quetiapine)
  • Latuda (Lurasidone)
  • Aristada (Aripiprazole Lauroxil)
  • Fanapt (Iloperidone)
  • Saphris (Asenapine)
  • Vraylar (Cariprazine)
• Third-Generation Antipsychotics
  • Abilify (Aripiprazole)
• Others
  • First-Generation Antipsychotics
  • Generics

Schizophrenia Drugs Market, By Treatment

• Market Overview
• Oral Antipsychotics
• Injectable Antipsychotics

Schizophrenia Drugs Market, By Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Schizophrenia Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Minerva Neurosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reliance Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karuna Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments